Selection and Warning of Evidence-Based Antidiabetic Medications for Patients With Chronic Liver Disease

10Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

The global prevalence of chronic liver disease and diabetes mellitus (DM) has gradually increased potentially due to changes in diet and lifestyle. The choice of antidiabetic medications for patients with coexisting DM and chronic liver disease is complicated. Severe liver injury may decrease the metabolism of antidiabetic medications, resulting in elevated drug concentrations and adverse effects. The choice of antidiabetic medications in patients with chronic liver disease has not been well studied. The long-term outcomes of antidiabetic medications in patients with chronic liver disease have gained attention recently. Herein, we reviewed relevant articles to extend our understanding on the selection and warning of antidiabetic medications for patients with chronic liver disease.

Cite

CITATION STYLE

APA

Yen, F. S., Hsu, C. C., Wei, J. C. C., Hou, M. C., & Hwu, C. M. (2022, February 16). Selection and Warning of Evidence-Based Antidiabetic Medications for Patients With Chronic Liver Disease. Frontiers in Medicine. Frontiers Media S.A. https://doi.org/10.3389/fmed.2022.839456

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free